Current research of the RAS in diabetes mellitus

Advances in Experimental Medicine and Biology

Volumn 690, Issue , 2010, Pages 131-153

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CALCITRIOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; IRBESARTAN; LOSARTAN; NATEGLINIDE; PERINDOPRIL; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; ROSIGLITAZONE; TELMISARTAN; TRANDOLAPRIL; UNCOUPLING PROTEIN 2; UNINDEXED DRUG; VALSARTAN; VILDAGLIPTIN; VITAMIN D; VITAMIN D RECEPTOR;

ARTICLE; CALCIUM INTAKE; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIET THERAPY; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PHOSPHATE INTAKE; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ANIMAL; MEDICAL RESEARCH; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D;

EID: 79956222662     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-90-481-9060-7_8     Document Type: Article

References (90)

1. Abuissa H, Jones PG, Marso SP and O'Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821-826, 2005. (Pubitemid 41224805)
2. Ahren B, Landin-Olsson, M, Jansson PA, Svensson, M, Holmes D and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084, 2004. (Pubitemid 38619835)
3. Ahren B. Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes. Bioessays 20:642-651, 1998. (Pubitemid 28422224)
4. Billaudel B, Faure A, Labriji-Mestaghanmi H and Sutter BC. Direct in vitro effect of 1,25- dihydroxyvitamin D3 on islets insulin secretion in vitamin deficient rats: influence of vitamin D3 pretreatment. Diabetes Metab.15:85-87, 1989. (Pubitemid 19140022)
5. Bland R, Maskovic D, Hills CE, Hughes SV, Chan SL, Squires PE and Hewison M. Expression of 25-hydroxyvitamin D3-1-a-hydroxylase in pancreatic islets. J. Steroid Biochem Mol Biol 89-90:121-125, 2004. (Pubitemid 38844271)
6. Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? Br J Nutr 79:315-327, 1998. (Pubitemid 28163893)
7. Boucher BJ, Mannan N, Noonan K, Hales CN and Evans SJW. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 38:1239-1245, 1995
8. Bourlon PM, Faure-Dussert A and Billaudel B. The de novo synthesis of numerous proteins is decreased during vitamin D3 deficiency and is gradually restored by 1,25-dihydroxyvitamin D3 repletion in the islets of Langerhans of rats. J Endocrinol 162:101-109, 1999. (Pubitemid 29336360)
9. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE and Wang PR. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315:688-695, 2005. (Pubitemid 41500734)
10. Cade C and Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 119:84-90, 1986. (Pubitemid 16100711)
11. Cheng Q, Law PK, De Gasparo M and Leung PS. Combination of DPP-IV inhibitor LAF237 with AT1receptor antagonist valsartan enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther 327:683-691, 2008.
12. Chiu KC, Chu A, Go VL and Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79:820-825, 2004. (Pubitemid 41103882)
13. Chu KY, Lau T, Carlsson PO and Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55: 367-374, 2006. (Pubitemid 43343265)
14. Chu KY and Leung PS. Angiotensin II type 1 receptor antagonism mediates uncoupling protein 2- driven oxidative stress and ameliorates pancreatic islet β-cell function in young type 2 diabetic mice. Antioxid Redox Signal 9:869-878, 2007. (Pubitemid 46919590)
15. Chu KY, Cheng Q, Chen C, Au LS, Seto SW, Tuo Y, Motin L, Kwan YW and Leung PS. Angiotensin II exerts glucose-dependent effects on Kv currents in mouse pancreatic beta cells via angiotensin II type 2 receptor. Am J Physiol 298:C313-C323, 2010.
16. Clark SA, StumpfWE, SarMand DeLucca HF. 1,25-dihydroxyvitamin D3 target cells in immature pancreatic islets. Am J Physiol 253:E99-E105, 1987.
17. Connell JM, MacKenzie SM, Freel EM, Fraser R and Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 29:133-154, 2008. (Pubitemid 351519688)
18. Dardenne O, Prud'homme J, Arabian A, Glorieux FH and St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 142:3135-3141, 2001. (Pubitemid 32575552)
19. Davidson HW, Rhodes CJ and Hutton JC. Intra-organellar calcium and pH control proinsulin cleavage in the pancreatic beta cell via two distinct site-specific endopeptidases. Nature 333: 93-96, 1988.
20. Diz DI, Jessup JA, Westwood BM, Bosch SM, Vinsant S, Gallagher PE, and Averill DB. Angiotensin peptides as neurotransmitters and neuromodulators in the dorsomedial medulla. Clin Exp Pharmacol Physiol 29:473-482, 2002. (Pubitemid 34535372)
21. Doyle ME and Egan JM. Mechansisms of action of GLP-1 in the pancreas. Pharmacol Ther 113:546-593, 2007.
22. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551-1562, 2006.
23. Elliott WJ and Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 369:201-207, 2007a (Correction ibid: 1518). (Pubitemid 46111014)
24. Elliott WJ and Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Correction. Lancet 369:1518, 2007b.
25. Erben RG, Soegiarto DW, Weber K, Zeitz U, Lieberherr M, Gniadecki R, Moller G, Adamski J and Balling R. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol 16: 1524-1537, 2002. (Pubitemid 34743672)
26. Forman JP, Giovannucci E, Holmes MD, Bishcoff-Ferrari HA, Tworoger SS, Willett WC and Curhan GC. Plasma 25-hydroxyvitamin D levels and risk of incident diabetes. Hypertension 49:1063-1069, 2007. (Pubitemid 351664326)
27. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC and Rodriguez-Iturbe B. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 74:1394-1402, 2008.
28. Green BD, Liu HK, McCluskey JT, Duffy NA, O'Harte FP, McClenaghan NH, and Flatt, PR. Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1. Diabetes Obes Metab 7:563-569, 2005. (Pubitemid 41150430)
29. Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, Modlin RL and Adams JS. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 103:316-321, 2007. (Pubitemid 46420518)
30. Holick MF. Vitamin D: A millenium perspective. J Cell Biochem 88:296-307, 2003.
31. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18:430-441, 2002. (Pubitemid 36041598)
32. Hypponen E, Boucher BJ, Berry DJ and Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: A cross-sectional study in the 1958 British Birth Cohort. Diabetes 57:298-305, 2008.
33. Ishida H and Norman AW. Demonstration of high affinity receptors for 1,25-dihydroxyvitamin D3 in rat pancreas. Mol Cell Endocrinol 60:109-117, 1988. (Pubitemid 19005696)
34. Kadowski S and Norman AW. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest 73:759-766, 1984. (Pubitemid 14156858)
35. Kampf C, Lau T, Olsson R, Leung PS and Carlsson PO. Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucosestimulated insulin secretion in revascularised syngeneic mouse islet grafts. Diabetologia 48: 1159-1167, 2005. (Pubitemid 40909652)
36. Kieffer TJ, McIntosh CH and Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995.
37. Kintscher U, Foryst-Ludwig A and Unger T. Inhibiting angiotensin type 1 receptor as a target for diabetes. Expert Opin Ther Targets 12:1257-1263, 2008.
38. Ko SH, Kwon HS, Kim SR, Moon SD, Ahn YB, Song KH, Son HS, Cha BY, Lee KW, Son HY, Kang SK, Park CG, Lee IK and Yoon KH. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commum 316:114-122, 2004.
39. Ko SH, Hong OK, Kim JW, Ahn YB, Song KH, Cha BY, Son HY, KimMJ, Jeong IK and Yoon KH. High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. J Cell Biochem 98:343-355, 2006.
40. Kobayashi K, Sumimoto H and Nawata. Increased expression of NAD(P)H oxidase in islets of animal models of type 2 diabetes and its improvement by an AT1receptor antagonist. Biochem Biophys Res Commun 332:927-933, 2005. (Pubitemid 40798176)
41. Kong J and Li YC. Effect of angiotensin II type 1 receptor antagonist and angiotensin-converting inhibitor on vitamin D receptor-null mice. Am J Physiol 285:R255-R261, 2003. (Pubitemid 36736524)
42. Krause R, Buhring M, Hopfenmuller W, Holick MF and Sharma AM. Ultraviolet B and blood pressure. Lancet 352:709-710, 1998.
43. Lam SK and Owen A. Incident diabetes in clinical trials of antihypertensive drugs. Lancet 369:1513-1514, 2007. (Pubitemid 46670293)
44. Lau T, Carlsson PO and Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47:240-248, 2004. (Pubitemid 38315360)
45. Lee S, Clark SA, Gill RK and Christakos S. 1,25-dihydroxyvitamin D3 and pancreatic β- cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology 134:1602-1610, 1994.
46. Leung PS and De Gasparo M. Novel peptides and proteins in diabetes mellitus. Curr Protein Pept Sci 10:1-107, 2009.
47. Leung KK and Leung PS. Effects of hyperglycemia on angiotensin II receptor type expression and insulin secretion in an INS-1E pancreatic beta-cell line. J Pancreas 9:290-299, 2008. (Pubitemid 351864889)
48. Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol 580: 31-37, 2007a. (Pubitemid 46470642)
49. Leung PS. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in type 2 diabetes. Diabet Med 24:110-116, 2007b. (Pubitemid 46174932)
50. Leung PS and De Gasparo M. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome. J Cardiometab Syndr 1:197-203, 2006.
51. Leung PS, Hayek A and De Gasparo M. Diabetes: new research and novel therapeutics. Int J Biochem Cell Biol 38:685-1022, 2006.
52. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W and Kong J. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89-90:387-392, 2004. (Pubitemid 38844316)
53. Li YC, Kong J, Wei M, Chen ZF, Liu SQ and Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238, 2002. (Pubitemid 34787360)
54. Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R and Demay MB. Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 94:9831-9835, 1997.
55. Lind L, Wengle B, Wide L and Ljunghall S. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am. J Hypertens 2:20-25, 1989. (Pubitemid 19031898)
56. Lind L, Lithell H, Skafors E, Wide L and Ljunghall S. Reduction in blood pressure by treatment with alphacidol: A double-blind, placebo-controlled study in subjects with impaired glucose tolerance. Acta Med Scand 223:211-217, 1988. (Pubitemid 18098224)
57. Lupi R, Guerra SD, Bugliani M, Boggi U, Mosca F, Torri S, Prato SD and Marchetti P. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol 154:355-361, 2006.
58. Mathieu C, Gysemans C, Giulietti A and Bouillon R. Vitamin D and diabetes. Diabetologia 48:1247-1257, 2005.
59. Malloy PJ, Eccleshall TR, Gross C, Van Maldergem L, Bouillon R and Feldman D. Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. J Clin Invest 99:297-304, 1997. (Pubitemid 27053470)
60. Mathieu C, Waer M, Laureys J, Rutgeerts O and Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25-dihydroxyvitamin D3. Diabetologia 37:552-558, 1994. (Pubitemid 24162425)
61. Nakayama M, Inoguchi T, Sonta T, Maeda Y, Sasaki S, Sawada F, Tsubouchi H, Sonoda N, Mest HJ and Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 48:616-620, 2005. (Pubitemid 40591214)
62. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S and Hellstrom PM. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304-311, 1999. (Pubitemid 29118862)
63. Norman AW. Vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147:5542-5548, 2006. (Pubitemid 44833469)
64. 2+ concentration in pancreatic β-cells through nongenomic signal transduction. Endocrinology 140:4760-4712, 1999.
65. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Eng J Med 358:1547-1559, 2008.
66. Paul M, Mehr AP and Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 86:747-803, 2006. (Pubitemid 44033382)
67. PEACE Trial Investigators. The prevention of events with angiotensin converting enzyme inhibition in stable coronary artery disease. N Eng J Med 351:2058-2068, 2004.
68. Prigeon RL, Quddusi S, Paty B and D'Alessio DA. Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285:E701-E707, 2003. (Pubitemid 37176420)
69. Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN and Goltzman D. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 98:7498-7503, 2001. (Pubitemid 32567977)
70. Repa JJ, Lund EG, Horton JD, Leitersdorf E, Russell DW, Dietschy JM and Turley SD. Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding. J Biol Chem 275:39685-39692, 2000. (Pubitemid 32058997)
71. Sato H, Uchiyama Y, Masushige S, Fukamizu A, Matsumoto T and Kato S. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16:391-396, 1997. (Pubitemid 27323308)
72. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: A meta-analysis of randomized clinical trials. Diabetes Metab 30:487-496, 2004a. (Pubitemid 40070350)
73. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: overview of physiological and biochemical mechanisms. Diabetes Metab 30:498-505, 2004b. (Pubitemid 40073639)
74. Scragg R, Sowers M and Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 20:713-719, 2007. (Pubitemid 46936167)
75. Scragg R, Sowers M and Bell C. Serum 25-hydroxyvitamin D, diabetes and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27:2813-2818, 2004. (Pubitemid 39565042)
76. Scragg R, Jackson R, Holdaway IM, Lim T and Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: A community-based study. Int J Epidemiol 19:559-563, 1990. (Pubitemid 20331800)
77. Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet irradiation. Int J Epidemiol 10:337-341, 1981. (Pubitemid 12164635)
78. Sergeev IN and Rhoten WB. 1,25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. Endocrinology 136:2852-2861, 1995.
79. Shao J, Iwashita N, Ikeda F, Ogihara T, Uchida T, Shimizu T, Uchino H, Hirose T, Kawamori R and Watada H. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on betacell function and morphology in db/db mice. Biochem Biophys Res Commun 344:1224-1233, 2006.
80. Staples JA, Ponsonby AL, Lim L and McMichael AJ. Ecological analysis of some immune-related disorders, including type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environ Health Perspect 111, 518-523, 2003. (Pubitemid 36546533)
81. St-Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, Chapin K, Depovere J, Mathieu C, Christakos S, Demay MB and Glorieux FH. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25- dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 141: 2658-2666, 2000. (Pubitemid 32269087)
82. Thorens B, Porret A, Buhler L, Deng SP, Morel P and Widmann C. Cloning and function expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist to the receptor. Diabetes 42:1678-1682, 1993. (Pubitemid 23318127)
83. Thorens B. Expression and cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89:8641-8645, 1992.
84. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC and Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53: 989-997, 2004. (Pubitemid 38436611)
85. Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van Herck E, Kato S, Bindels RJ, Collen D, Carmeliet P, Bouillon R and Carmeliet G. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci USA 98: 13324-13329, 2001. (Pubitemid 33051361)
86. Wang Q and Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45:1263-1273, 2002.
87. Wang Q and Jin T. The role of insulin signaling in the development of β-cell dysfunction and diabetes. Islets 1:95-105, 2009.
88. Weishaar RE and Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest 79:1706-1712, 1987.
89. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Yusef S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Eng J Med 342:145-153, 2000.
90. Zander M, Madsbad S, Madsen JL and Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallelgroup study. Lancet 359:824-830, 2002. (Pubitemid 34233752)